We are delighted to announce our symposium on EEG biomarkers of brain health and dementia.
Recent international guidelines for research in aging-related neurodegenerative diseases such as Alzheimer’s disease and related disorders belonging to dementia encourage the use of biomarkers to ascertain the diagnosis or the risk of the disease as well as the prediction and monitoring of disease progression. Those biomarkers derive from laboratory analysis of cerebrospinal fluid (CSF) collected by lumbar puncture and neuroimaging scans including structural magnetic resonance imaging (sMRI) and positron emission tomography (PET) or single photon emission computerized tomography (SPECT). These techniques are quite informative but invasive and/or expensive for large screening purposes, especially in lower- and middle-income countries. Furthermore, they maybe not viable in all regions of Latin American countries (LACs). This raises an important challenge as dementia is one of the most dramatic global health problems. To tackle this challenge, other techniques exploring brain function are under evaluation to produce biomarkers to be used in the field of dementia.